Next generation drug screening for precision oncology

CBmed can bring an innovative quality-assured workflow to test the effect of drugs on patient-derived tumor cells with a particular interest on ovarian cancer and glioblastoma. The method we bring on truly furnishes a personalized medicine approach as the individual patient response to drugs can be established. Furthermore, combining these readouts with other -omics data can provide unprecedented access to precision oncology.

In the video attached to this description, you can learn more about this technology which we would like to bring on to EU projects.